Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2022-05-11 AGM Information
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)
AGM Information Classification · 99% confidence The document explicitly states it contains the 'Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)' and details resolutions passed at the 'AGM' regarding financial statements adoption, board elections, remuneration guidelines, and share authorization. This content directly corresponds to the materials presented or decided upon during an Annual General Meeting. Therefore, the classification is AGM-R (AGM Information). The document length (4658 chars) is substantial enough to be the bulletin itself, not just a short announcement of the meeting.
2022-05-11 English
Interim report January - March 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report Jan 1-Mar 31, 2022' for Vicore Pharma Holding AB. It contains comprehensive financial statements, including a summary of the period, financial overview, CEO comments, business focus areas, and detailed financial tables for the group and parent company. It is a full quarterly report, not an announcement or a summary, and fits the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-05 English
Delårsrapport januari - mars 2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Vicore Pharma Holding AB for the period 1 January to 31 March 2022. It contains comprehensive financial statements, management commentary (VD-ord), business updates, and key performance indicators. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-05 Swedish
Kallelse till årsstämma i Vicore Pharma Holding AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Vicore Pharma Holding AB (publ)" which translates to 'Notice of Annual General Meeting' in Swedish. The text details the procedures for a general meeting, including voting by mail (poströstning), the proposed agenda (dagordning) covering the election of the board, auditors, and approval of remuneration guidelines, and the date of the meeting (May 11, 2022). This content directly corresponds to the materials prepared for shareholders ahead of an Annual General Meeting (AGM). While it contains elements related to remuneration (DEF 14A) and governance (CGR), the primary purpose and structure of the document is the formal notice and agenda for the AGM itself. Therefore, the most appropriate classification is AGM Information (AGM-R).
2022-04-07 Swedish
Notice of annual general meeting of Vicore Pharma Holding AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of annual general meeting of Vicore Pharma Holding AB (publ)" and details the procedures for shareholders to participate via advance voting, the proposed agenda items (including election of directors, approval of reports, and remuneration guidelines), and specific dates related to the meeting (May 11, 2022). This content directly corresponds to the materials distributed to shareholders in preparation for or as part of the Annual General Meeting. Therefore, the classification is AGM-R (AGM Information).
2022-04-07 English
Annual Report 2021
Annual Report Classification · 100% confidence The document is titled 'Årsredovisning 2021' (Annual Report 2021) for Vicore Pharma Holding AB. It contains comprehensive sections including a summary of the period, CEO comments, market overview, program overviews, financial statements for the group and parent company, notes, board and management information, and an audit report. This matches the definition of an Annual Report (10-K). FY 2021
2022-04-07 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.